Citius Oncology Inc (NASDAQ: CTOR)’s stock price has increased by 54.99 compared to its previous closing price of 0.67. However, the company has seen a 45.17% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-14 that CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Is It Worth Investing in Citius Oncology Inc (NASDAQ: CTOR) Right Now?
Additionally, the 36-month beta value for CTOR is 0.30. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTOR is 3.52M and currently, short sellers hold a 0.79% ratio of that float. The average trading volume of CTOR on March 31, 2025 was 128.15K shares.
CTOR’s Market Performance
CTOR stock saw a decrease of 45.17% in the past week, with a monthly decline of -13.39% and a quarterly a decrease of 7.36%. The volatility ratio for the week is 27.19%, and the volatility levels for the last 30 days are 16.95% for Citius Oncology Inc (CTOR). The simple moving average for the last 20 days is 33.08% for CTOR stock, with a simple moving average of -72.70% for the last 200 days.
Analysts’ Opinion of CTOR
Many brokerage firms have already submitted their reports for CTOR stocks, with Maxim Group repeating the rating for CTOR by listing it as a “Buy.” The predicted price for CTOR in the upcoming period, according to Maxim Group is $3 based on the research report published on November 27, 2024 of the previous year 2024.
CTOR Trading at -0.95% from the 50-Day Moving Average
After a stumble in the market that brought CTOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.90% of loss for the given period.
Volatility was left at 16.95%, however, over the last 30 days, the volatility rate increased by 27.19%, as shares sank -0.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.23% lower at present.
During the last 5 trading sessions, CTOR rose by +46.44%, which changed the moving average for the period of 200-days by -90.68% in comparison to the 20-day moving average, which settled at $0.7749. In addition, Citius Oncology Inc saw -10.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTOR
Equity return is now at value 3.49, with 3.44 for asset returns.
Based on Citius Oncology Inc (CTOR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1.
Currently, EBITDA for the company is -20.57 million with net debt to EBITDA at -0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, Citius Oncology Inc (CTOR) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
